List of Excipients in Branded Drug PERIOGARD (CHLORHEXIDINE GLUCONATE)

« Back to Dashboard

Generic Drugs Containing PERIOGARD (CHLORHEXIDINE GLUCONATE)

Company	Ingredient	NDC	Excipient
Colgate Oral Pharmaceuticals Inc	chlorhexidine gluconate	0126-0035	ALCOHOL
Colgate Oral Pharmaceuticals Inc	chlorhexidine gluconate	0126-0035	FD&C BLUE NO. 1
Colgate Oral Pharmaceuticals Inc	chlorhexidine gluconate	0126-0035	GLYCERIN
Colgate Oral Pharmaceuticals Inc	chlorhexidine gluconate	0126-0035	POLYSORBATE 20
Colgate Oral Pharmaceuticals Inc	chlorhexidine gluconate	0126-0035	SACCHARIN SODIUM
Colgate Oral Pharmaceuticals Inc	chlorhexidine gluconate	0126-0035	WATER

What are the Most Frequently-Used Excipients in PERIOGARD (CHLORHEXIDINE GLUCONATE)?

# Of NDCs	Excipient
1	ALCOHOL
1	FD&C BLUE NO. 1
1	GLYCERIN
1	POLYSORBATE 20
1	SACCHARIN SODIUM
1	WATER

Periogard Chlorhexidine Gluconate: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 3, 2026

Periogard is a prescription 0.12% chlorhexidine gluconate oral rinse for reducing gingival inflammation and oral microbial burden. Its core formulation uses established, low-cost excipients, leaving limited composition-of-matter protection but meaningful opportunities in alcohol-free delivery, taste masking, preservative systems, packaging, and differentiated dosing. The principal commercial opportunity is not a new Periogard copy. It is a better-tolerated chlorhexidine product with comparable antimicrobial performance and a defensible formulation or device profile.

What is Periogard and what is its FDA status?

Periogard contains chlorhexidine gluconate at a concentration of 0.12%, equivalent to 1.2 mg/mL chlorhexidine gluconate. It is administered as an oral rinse, commonly at 15 mL for 30 seconds twice daily after toothbrushing. The product is indicated as part of a professional program for treating gingivitis, including reduction of gingival inflammation, redness and bleeding.

Attribute	Periogard profile
Active ingredient	Chlorhexidine gluconate
Strength	0.12% oral rinse
Dosage form	Aqueous oral solution
Route	Oral, topical mouth rinse
Regulatory category	Prescription drug
Reference product	PerioGard / chlorhexidine gluconate oral rinse
Primary use	Gingivitis management
Typical administration	15 mL, twice daily
Orange Book status	Product-specific listing must be verified against the current FDA Orange Book
Biosimilar pathway	Not applicable
Main competitive products	Peridex, generic chlorhexidine gluconate oral rinses, professional dental products

FDA labeling identifies Periogard as a prescription oral rinse and warns against swallowing, routine use by children, and use as a substitute for oral hygiene procedures. Common adverse effects include tooth and oral-surface staining, increased calculus formation, altered taste and oral irritation (FDA, 2024).

What are the key FDA regulatory milestones?

Chlorhexidine oral rinses have been marketed for decades. The original regulatory pathway for branded chlorhexidine gluconate oral rinse products predates modern formulation patent strategies. Current competition is primarily established through abbreviated new drug applications, not through biosimilar applications or complex biologic comparability programs.

The regulatory burden for a new generic or line extension is concentrated in:

• Pharmaceutical equivalence to the reference product.
• Assay and impurity control for chlorhexidine gluconate.
• Microbiological quality and preservative effectiveness.
• Stability across the proposed shelf life.
• Container-closure compatibility.
• Demonstration that the product does not create unacceptable differences in labeling, dosing or clinical use.

A materially different formulation may require a new drug application or a supplemental pathway rather than a straightforward generic filing.

What excipients are used in Periogard?

Periogard uses a conventional excipient platform intended to solubilize chlorhexidine, provide acceptable mouthfeel, preserve the aqueous product and mask the active ingredient's bitterness.

Public labeling identifies the following inactive ingredients for Periogard or closely related chlorhexidine gluconate oral-rinse products:

Excipient category	Representative excipient	Functional purpose
Vehicle	Purified water	Solvent and primary carrier
Co-solvent	Alcohol	Solubilization, sensory effect and microbial control
Humectant	Glycerin	Mouthfeel, moisture retention and viscosity
Surfactant or solubilizer	Polysorbate 20 or related solubilizer, depending on product	Flavor and formulation compatibility
Sweetener	Sodium saccharin	Taste masking
Flavor	Proprietary flavor system	Reduction of bitterness and medicinal notes
Colorant	FD&C Blue No. 1	Product identification and appearance

Exact excipient composition can vary between Periogard, Peridex and generic chlorhexidine gluconate products. A sponsor should rely on the current product label, inactive-ingredient statement and regulatory filing rather than assume that every 0.12% product uses the same excipient system (DailyMed, 2024a; DailyMed, 2024b).

Why is alcohol used in chlorhexidine mouth rinse?

Alcohol can improve solubilization, help control microbial contamination and influence sensory perception. It also creates commercial constraints. Alcohol-containing products can produce burning, dryness and poor acceptability for some patients. The alcohol content may limit use by certain patient groups and creates a clear differentiation opportunity for alcohol-free products.

Alcohol is not required to achieve chlorhexidine's antiseptic activity. The technical challenge is replacing its formulation and sensory functions without causing precipitation, instability, excessive foaming or reduced antimicrobial performance.

What excipient strategies can differentiate a Periogard competitor?

The strongest formulation strategies target tolerability, taste, staining and ease of use. Chlorhexidine's antimicrobial mechanism is difficult to differentiate through the active ingredient alone because the concentration and dosing convention are already established.

Alcohol-free systems

An alcohol-free formulation can use a combination of:

• Water and glycerin as the principal vehicle.
• Nonionic solubilizers compatible with chlorhexidine.
• Low-foaming surfactants.
• Polyols for mouthfeel.
• High-intensity sweeteners for bitterness control.
• A compatible flavor system.
• A validated antimicrobial preservation strategy.

The main development risk is compatibility. Chlorhexidine is cationic and can interact with anionic excipients, polymers, flavor components and impurities. Anionic surfactants and certain acidic ingredients can reduce available chlorhexidine or cause precipitation. Formulators should screen excipients for ionic charge, binding capacity, pH effects and adsorption to packaging surfaces.

Taste-masking systems

Taste is a major commercial barrier because chlorhexidine has a bitter, medicinal profile and can alter taste perception. Opportunities include:

• Layered flavor systems that mask both initial bitterness and aftertaste.
• Polyol-based mouthfeel modification.
• Encapsulation or complexation approaches that reduce immediate receptor exposure.
• Controlled-release films or mucoadhesive systems.
• Low-intensity cooling agents selected for oral compatibility.
• Sweetener combinations rather than reliance on sodium saccharin alone.

Taste-masking claims should be supported by human sensory data. A better flavor profile can support adherence but must not impair chlorhexidine availability or antimicrobial activity.

Reduced-staining formulations

Tooth and tongue staining is a recognized chlorhexidine limitation. A formulation program could seek to reduce staining through:

• Lower exposure to chromogenic complexes.
• Changes in ionic environment.
• Reduced retention on pellicle and oral surfaces.
• Rinse-and-clear designs.
• Alternate dosing schedules supported by clinical evidence.
• Combination with compatible anti-staining agents.

This area has patent potential, but it presents a demanding proof standard. A sponsor would need comparative staining data under controlled conditions and evidence that antimicrobial activity remains clinically meaningful.

Preservative-free or low-preservative products

A unit-dose, pump or sterile-packaged product could reduce dependence on conventional preservatives. Commercial benefits include positioning for sensitive patients and institutional settings. The tradeoff is higher packaging cost, more complex manufacturing and increased container-closure validation.

A preservative-free product is unlikely to win on price alone. It needs a defined use case, such as dental surgery, post-procedure care, hospital dispensing or patients with intolerance to conventional excipients.

What patents protect Periogard and chlorhexidine gluconate oral rinses?

The original active-ingredient protection for chlorhexidine is expired. Periogard's commercial position does not depend on a live chlorhexidine composition-of-matter patent.

Are there current formulation patents covering Periogard?

No broadly recognized, high-value patent barrier is apparent from the legacy product's conventional formulation profile. The relevant protection is more likely to involve:

• Product-specific formulation claims.
• Alcohol-free chlorhexidine systems.
• Taste-masking compositions.
• Anti-staining combinations.
• Delivery devices and dispensing mechanisms.
• Manufacturing processes.
• Packaging and stability solutions.
• Method-of-use claims for dental indications.

Patent status must be confirmed in current USPTO records, FDA Orange Book listings and litigation databases. A company evaluating a Periogard generic should not assume that the absence of an obvious composition patent eliminates all freedom-to-operate risk.

What is the Orange Book status of Periogard?

The Orange Book determines whether FDA-listed patents and regulatory exclusivities affect an abbreviated new drug application. Chlorhexidine gluconate oral rinse products may have limited or no currently operative Orange Book patent protection, but the relevant product entry, NDA or listed reference product should be checked in the current edition.

For a generic sponsor, the key questions are:

1. Whether Periogard or a related reference product is the applicable RLD.
2. Whether any listed patents remain unexpired.
3. Whether a Paragraph IV certification is required.
4. Whether the product is eligible for 180-day generic exclusivity.
5. Whether labeling differences create a need for a suitability petition or a different regulatory pathway.

When does Periogard lose exclusivity?

Periogard's core exclusivity has effectively expired because chlorhexidine gluconate oral rinse products have been marketed for many years and generic products are available. There is no biosimilar exclusivity period because the product is a small-molecule oral solution, not a biologic.

The practical exclusivity analysis is therefore:

Protection type	Periogard assessment
Active-ingredient patent	Expired
Original formulation protection	No apparent current barrier of broad commercial significance
New chemical entity exclusivity	Expired
Orphan exclusivity	Not applicable
Pediatric exclusivity	No current product-level barrier apparent
Biosimilar exclusivity	Not applicable
FDA 180-day generic exclusivity	Depends on the specific ANDA and Paragraph IV history
Trademark protection	Brand and trade dress may remain protected
Trade-secret protection	Possible for flavor, process and supplier specifications

Trademark rights can limit naming and packaging but do not prevent approval of a therapeutically equivalent generic under a compliant label.

Which companies are challenging or competing with Periogard?

Competition exists at three levels.

Generic manufacturers

Multiple manufacturers and repackagers have marketed chlorhexidine gluconate oral rinse products, including products sold under generic labels and dental-distribution brands. The exact active supplier and finished-dose manufacturer can differ by National Drug Code and market channel.

Generic competition generally focuses on:

• Low acquisition cost.
• Wholesaler availability.
• Private-label supply.
• Dental-office contracts.
• Bottle and cap compatibility.
• Institutional purchasing.

Branded dental products

Peridex is the best-known branded comparator in the U.S. chlorhexidine rinse market. Other competitors include professional-use chlorhexidine rinses and international products with different concentrations, flavors, alcohol content or pack sizes.

Adjacent oral-care products

Essential-oil rinses, cetylpyridinium chloride products, povidone-iodine products and prescription fluoride rinses compete for oral-care spending. These products may have better consumer acceptability, but they do not necessarily provide the same chlorhexidine activity or clinical positioning.

What commercial opportunities exist for Periogard excipients?

The most attractive opportunities are specialized rather than broad commodity substitution.

Opportunity	Commercial rationale	Main barrier
Alcohol-free 0.12% rinse	Better tolerability and wider patient acceptance	Stability, solubilization and equivalence
Low-staining chlorhexidine rinse	Addresses a major adherence problem	Clinical proof and mechanism complexity
Premium taste-masked product	Supports adherence and dental-office adoption	Sensory performance and cost
Unit-dose packaging	Reduces dosing errors and contamination risk	Packaging economics
Pump or metered dispenser	Improves convenience and reduces overuse	Device qualification
Pediatric-adjacent formulation	Could improve handling, but indication and safety limits apply	Swallowing risk and regulatory constraints
Hospital or post-surgical format	Supports procedure-based procurement	Institutional evidence and contracting
Custom flavor or private label	Allows dental distributors to differentiate	Limited switching costs

Excipient suppliers can capture value through proprietary solubilizers, flavor systems, polymeric taste-maskers, low-foaming surfactants and packaging-compatible preservation systems. Finished-dose manufacturers can use these components to create line extensions with higher gross margins than conventional generic oral solutions.

What patent opportunities exist for a new Periogard formulation?

A defensible patent program should focus on measurable technical outcomes rather than a broad list of conventional excipients.

Potential claim areas include:

• Specific chlorhexidine-to-solubilizer ratios.
• Alcohol-free formulations with defined pH and stability limits.
• Taste-masking systems that preserve antimicrobial activity.
• Anti-staining compositions with comparative staining results.
• Low-foaming oral-rinse systems.
• Unit-dose or metered-dose delivery devices.
• Container-closure systems that reduce adsorption or leachables.
• Manufacturing processes that control chlorhexidine degradation or precipitation.
• Methods for reducing adverse sensory effects while maintaining gingivitis efficacy.

Broad claims to "chlorhexidine plus glycerin and flavor" are likely to face prior-art pressure. Stronger protection would combine narrow compositional ranges with stability, sensory or clinical performance data.

What generic launch risks exist for Periogard?

A conventional generic oral solution has a relatively low patent risk but still faces commercial and regulatory risks:

1. Reference-product selection risk. Periogard, Peridex and other chlorhexidine products may have different regulatory histories and excipient compositions.
2. Formulation equivalence risk. A change in alcohol, flavor, surfactant or pH can affect pharmaceutical equivalence and labeling.
3. Supply-chain risk. Chlorhexidine gluconate quality, flavor systems and packaging components can affect batch release.
4. Manufacturing risk. Precipitation, foaming, color variation and container adsorption can reduce yield.
5. Market-price risk. Multiple generic suppliers can rapidly compress margins.
6. Channel risk. Dental distribution and retail pharmacy channels have different purchasing dynamics.
7. Litigation risk. A novel formulation may attract patent claims even when the legacy product has weak protection.

How does Periogard compare with a differentiated chlorhexidine product?

Criterion	Conventional Periogard-type generic	Differentiated formulation
Development cost	Low to moderate	Moderate to high
Regulatory complexity	Relatively limited	Higher if formulation or labeling changes materially
Patent opportunity	Low	Moderate to high
Price competition	Severe	Lower if clinical or sensory benefit is credible
Patient adherence	Limited by staining and taste	Potentially improved
Dental-office adoption	Driven by price and availability	Driven by tolerability and outcomes
Manufacturing complexity	Low	Moderate to high
Commercial margin	Generic-level	Potential premium

What litigation and settlement issues affect Periogard?

No major, current patent litigation barrier is broadly associated with the legacy chlorhexidine gluconate oral-rinse market. A sponsor must still review:

• FDA Orange Book patent listings.
• Paragraph IV certifications and ANDA litigation.
• Hatch-Waxman settlements involving the applicable RLD.
• Trademark and trade-dress disputes.
• Supplier indemnification terms.
• Patent families covering alcohol-free, taste-masked or anti-staining formulations.

Settlement agreements can delay generic entry even when a patent appears weak. Their commercial terms may include a licensed entry date, authorized generic supply, or restrictions tied to specific formulation versions.

Key Takeaways

• Periogard is a 0.12% chlorhexidine gluconate prescription oral rinse with an established, conventional excipient platform.
• The active ingredient and legacy product protection are expired or commercially weak as exclusivity barriers.
• Alcohol-free, low-staining and taste-masked formulations offer the clearest product differentiation.
• Chlorhexidine's cationic chemistry creates meaningful compatibility risks with anionic excipients and certain flavor systems.
• Generic entry is technically feasible but vulnerable to price compression.
• The strongest new patent opportunities combine defined excipient ratios with stability, sensory, staining or delivery performance.
• Biosimilar risk is irrelevant because Periogard is a small-molecule oral solution.
• Commercial value is more likely to come from adherence, dental-office positioning and specialized packaging than from the base rinse itself.

FAQs

Is Periogard alcohol-free?

Periogard-type formulations may contain alcohol, depending on the specific product and current labeling. The approved product label should be checked for the exact inactive-ingredient statement.

Can chlorhexidine gluconate be formulated without sodium saccharin?

Yes. Sodium saccharin can be replaced or supplemented with other compatible high-intensity sweeteners, but the replacement must be evaluated for taste, stability, microbial quality and chlorhexidine compatibility.

Does chlorhexidine gluconate require a preservative?

Not necessarily. A preserved multidose solution can use an antimicrobial preservation strategy, while unit-dose or specialized packaging may reduce or eliminate the need for conventional preservatives. The selected design requires microbiological validation.

Can a new chlorhexidine mouth rinse obtain FDA approval as a generic?

A product that meets the applicable requirements for pharmaceutical equivalence, labeling, quality and regulatory sameness may be eligible for an ANDA. A materially different formulation, indication or delivery system may require a different FDA pathway.

What is the highest-value excipient opportunity in chlorhexidine oral rinses?

A validated alcohol-free taste-masking system with reduced staining potential has the strongest combination of patient benefit, commercial differentiation and formulation patent potential.

References

1. DailyMed. (2024a). Periogard: Chlorhexidine gluconate oral rinse, 0.12% prescribing information. U.S. National Library of Medicine.

2. DailyMed. (2024b). Peridex: Chlorhexidine gluconate oral rinse, 0.12% prescribing information. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug product labeling for chlorhexidine gluconate oral rinse products. FDA.

5. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.